MariTide (maridebart cafraglutide)

Used for

• Weight loss
• Type 2 diabetes (studied)

How it works

The GLP-1 part lowers appetite. The antibody part blocks the GIP receptor (the opposite of tirzepatide, which stimulates it) and keeps the drug in the body for weeks, so it is dosed monthly.

What the research shows

• Phase 2 (52 weeks, 465 adults with obesity): 140, 280 or 420 mg every 4 weeks, or 420 mg every 8 weeks, lost 12.3–16.2% of body weight vs 2.5% on placebo (all participants analysis).
• In 127 people with obesity and type 2 diabetes: 8.4–12.3% weight loss vs 1.7%, and HbA1c fell 1.2–1.6 points vs a 0.1 rise.
• Stomach side effects were common, and less frequent with a step-up and a lower starting dose than with the full dose from the first injection.

Dosing

Dosing isn’t listed on the public site. In the app, each published option is shown with its source (a drug label, a clinical guideline, a trial or community reports) and can be turned into a protocol you review.

Side effects

• Nausea, especially after a dose step
• Constipation or diarrhea
• Reflux, burping
• Lower appetite and thirst: dehydration risk
• Nausea and vomiting, more often when started at a full dose

Cautions

• Not for anyone with a personal or family history of medullary thyroid cancer or MEN2.
• Pancreatitis and gallbladder problems are uncommon but reported; severe belly pain needs urgent care.
• Rapid weight loss costs muscle too: keep protein high and keep lifting.
• Stop before planned surgery or sedation per your doctor (slower stomach emptying).
• Used only in Amgen trials: anything sold online under this name or "AMG 133" cannot be checked.
• Research-chemical vials have no quality control: purity, dose and sterility vary. Third-party testing helps but is no guarantee.

Storage

More in Weight & metabolic